ReviewCurrent gene therapy2013
Human pluripotent stem cells for modelling human liver diseases and cell therapy.
Review in Current gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 56 citations in OpenAlex.
- MiR-122-5p inhibits the epithelial mesenchymal transition of liver cancer cells by inducing hiPSCs to differentiate into hepatocyte-like cells.European journal of histochemistry : EJH · 2025Article
- Cell therapy in end-stage liver disease: replace and remodel.Stem cell research & therapy · 2023Review
- Multicellular Liver Organoids: Generation and Importance of Diverse Specialized Cellular Components.Cells · 2023Review
- Article
- Induced Pluripotent Stem Cells for Treatment of Alzheimer's and Parkinson's Diseases.Biomedicines · 2022Review
- Production and cryopreservation of definitive endoderm from human pluripotent stem cells under defined and scalable culture conditions.Nature protocols · 2021Article
- Pluripotent-Stem-Cell-Derived Hepatic Cells: Hepatocytes and Organoids for Liver Therapy and Regeneration.Cells · 2020Review
- A small molecule Hedgehog agonist HhAg1.5 mediated reprogramming breaks the quiescence of noninjured liver stem cells for rescuing liver failure.Translational research : the journal of laboratory and clinical medicine · 2019Article
- Heterogeneous Nuclear Ribonucleoproteins Involved in the Functioning of Telomeres in Malignant Cells.International journal of molecular sciences · 2019Review
- Calcium Signaling in Cholangiocytes: Methods, Mechanisms, and Effects.International journal of molecular sciences · 2018Review
- Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis.Canadian journal of gastroenterology & hepatology · 2018Review
- Molecular and functional variation in iPSC-derived sensory neurons.Nature genetics · 2018Article
- Cancer in a dish: progress using stem cells as a platform for cancer research.American journal of cancer research · 2018Review
- Elongation of Axon Extension for Human iPSC-Derived Retinal Ganglion Cells by a Nano-Imprinted Scaffold.International journal of molecular sciences · 2017Article
- Cell sources for in vitro human liver cell culture models.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Minireview: Genome Editing of Human Pluripotent Stem Cells for Modeling Metabolic Disease.Molecular endocrinology (Baltimore, Md.) · 2016Review
- The Use of Induced Pluripotent Stem Cells for the Study and Treatment of Liver Diseases.Current protocols in toxicology · 2016Review
- A Convenient and Efficient Method to Enrich and Maintain Highly Proliferative Human Fetal Liver Stem Cells.Rejuvenation research · 2015Article
- Development and characterization of human-induced pluripotent stem cell-derived cholangiocytes.Laboratory investigation; a journal of technical methods and pathology · 2015Article
- Tonsil-derived mesenchymal stem cells ameliorate CCl4-induced liver fibrosis in mice via autophagy activation.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
The liver is affected by many types of diseases, including metabolic disorders and acute liver failure. Orthotopic liver transplantation (OLT) is currently the only effective treatment for life-threatening liver diseases but transplantation of allogeneic hepatocytes has now become an alternative as it is less invasive than OLT and can be performed repeatedly. However, this approach is hampered by the shortage of organ donors, and the problems related to the isolation of high quality adult hepatocytes, their cryopreservation and their absence of proliferation in culture. Liver is also a key organ to assess the pharmacokinetics and toxicology of xenobiotics and for drug discovery, but appropriate cell culture systems are lacking. All these problems have highlighted the need to explore other sources of cells such as stem cells that could be isolated, expanded to yield sufficiently large populations and then induced to differentiate into functional hepatocytes. The presence of a niche of "facultative" progenitor and stem cells in the normal liver has recently been confirmed but they display no telomerase activity. The recent discovery that human induced pluripotent stem cells can be generated from somatic cells has renewed hopes for regenerative medicine and in vitro disease modelling, as these cells are easily accessible. We review here the present progresses, limits and challenges for the generation of functional hepatocytes from human pluripotent stem cells in view of their potential use in regenerative medicine and drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.